Brought to you by:
Esprit BTK: Drug-eluting resorbable scaffold poised as first-line therapy for below-the-knee CLTI
This advertorial is sponsored by Abbott. “We now have something on label and FDA [Food and Drug Administration] approved that we can use as a first-line therapy for tibial vessels,” Richard Pin, MD, chief of vascular surgery at Southcoast Health…
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for below-the-knee arteries
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration (FDA)-approved Esprit BTK everolimus-eluting resorbable scaffold system (Abbott Vascular) in patients with the most severe form…
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year in LIFE-BTK analysis
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of infrapopliteal artery disease, with investigators predicting more significant results in the longer term. Sharing this finding…
TCT 2023: LIFE-BTK breathes life into drug-eluting resorbable scaffolds in breakthrough for below-the-knee arteries
Results of the LIFE-BTK randomized controlled trial have just been presented at TCT 2023 (Oct. 23–26) in San Francisco. The data show that, in patients with chronic limb-threatening ischemia (CLTI) due to infrapopliteal artery disease, an everolimus-eluting resorbable scaffold was…